Medivir AB (MVRBF) Release: New Simeprevir Data Will Be Presented At The International Liver Congress 2014 Of The European Association For The Study Of The Liver, (EASL)
3/24/2014 9:07:58 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that new data from the clinical development program for simeprevir in the treatment of genotype 1 or genotype 4 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease will be presented at The International Liver Congress of the European Association for the study of the Liver (EASL). The International Liver Congress 2014 will take place from April 9-13 in London, United Kingdom.
Help employers find you! Check out all the jobs and post your resume.
comments powered by